Conditions: Breast Cancer Metastasis
Keywords: Recurrent, locally-advanced, or 'triple negative' metastatic breast cancer
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 55
Healthy volunteers: no

Brief summary:
This study will determine whether the investigational drug dasatinib is effective in treatment of women with progressive advanced triple-negative breast cancer.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Dasatinib intervention 2: Dasatinib
Intervention descriptions: intervention 1: Tablets, Oral, 100 mg, twice daily as long as the patient benefits (avg \<6 months) intervention 2: Tablets, Oral, 70 mg, twice daily as long as the patient benefits (avg \<6 months)

Protocol document: